「從灣區啓航:”南海I號”與海上絲綢之路」展覽開幕

香港, 2024年8月16日 – (亞太商訊 via SeaPRwire.com) – 由發展局、國家文物局和澳門特別行政區政府社會文化司合辦的「從灣區啓航:『南海I號』與海上絲綢之路」展覽於八月十五日舉行開幕禮。展覽展出「南海I號」遠洋商船的出土文物及粵港澳三地的相關文物,以展示粵港澳大灣區在海上絲綢之路…

卫龙美味公佈2024年中期業績

香港, 2024年8月16日 – (亞太商訊 via SeaPRwire.com) – 中國辣味休閒食品行業龍頭企業,卫龙美味全球控股有限公司(「卫龙美味」或「集團」)及附屬公司(「集團」)(香港聯交所股票代碼:09985)公佈截至2024年6月30日止六個月(「期內」)未經審核之中期業績。 2024年上半…

第四範式發佈2024年中期業績

財務摘要︰– 2024年上半年總收入人民幣18.67億元,同比增長27.1%   – 先知AI平台業務收入為人民幣 12.51億元,同比增長65.4%,占總收入的比例升至67.0%   – SHIFT智能解決方案業務收入為人民幣4.53億元,占總收入的24.3%   – …

Genes Tech Group Announces 2024 Interim Results

HONG KONG, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – Genes Tech Group Holdings Co. Ltd (“Genes Tech Group” or “The Group”; Stock Code: 8257.HK) announces its interim results for the six months ended 30 June, 2024 (“the period”). During the period, the Group recorded the total revenue of approximately NTD535.01 million, Total comprehensive […]

AsiaMedic continues growth streak with 23% increase in revenue for First Half ended 30 June 2024

SINGAPORE, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – SGX Catalist-listed AsiaMedic Limited (the “Company” and together with its subsidiaries, the “Group”) announced its financial results for the financial period ended 30 June 2024 (“1H2024”). The Group’s 1H2024 revenue increased by S$2.4 million or 23% from S$10.7 million for 1H2023 to S$13.2 million due to […]

Kincora Participation in the Sharewise Webinar

Melbourne, Australia–(ACN Newswire via SeaPRwire.com – August 14, 2024) – Kincora Copper Limited (ASX: KCC) (TSXV: KCC) (Kincora or the Company) is pleased to be participating in the Sharewise Webinar to be held today, Thursday August 15th, from 1:30pm Australian Eastern Standard Time (AEST). President & CEO Sam Spring will provide investors and shareholders an […]

Solar District Cooling Group Berhad Signs Underwriting Agreement with Mercury Securities Sdn Bhd for Its IPO on the ACE Market of Bursa Malaysia Securities Berhad

KUALA LUMPUR, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – Solar District Cooling Group Berhad (“SDCG”) is pleased to announce that it has entered into an underwriting agreement with Mercury Securities Sdn Bhd (“Mercury Securities”) today for its upcoming initial public offering (“IPO”) on the ACE Market of Bursa Malaysia Securities Berhad. 1.Mr Chris […]

靖洋集團公佈2024年中期業績

香港, 2024年8月14日 – (亞太商訊 via SeaPRwire.com) – 靖洋集團控股有限公司(「靖洋集團」或「集團」,股份代號:8257.HK)宣佈截至 2024年6月30日止六個月(「期內」)之中期業績。期內,集團總收益約新台幣535.01百萬元。本公司擁有人應佔期間全面收益總額約新台幣3…

Kincora and AngloGold Ashanti’s First Drilling Program

The first ever copper-gold focused drilling program at the northern portion of the Nyngan Project will shortly commence with earn-in partner AngloGold Ashanti Australia (AngloGold Ashanti). New district-scale potential with up to eight large intrusive complex targets to be drill-tested for the first time in this initial first phase program. Approximately 6 to 8 drill […]

Experience Eternal Romance with Exquisite Blue Diamonds by ALUXE

SINGAPORE, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive “Lovers” collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair. ALUXE […]

Experience Eternal Romance with Exquisite Blue Diamonds

SINGAPORE, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive “Lovers” collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair. ALUXE […]

Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results

Development Highlights – During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China (“NMPA”), namely Andewei (Benmelstobart Injection), Anboni (Unecritinib capsules), Anluoqing (Envonalkib capsules) and Beilelin (Liraglutide Injection), three of which are national category 1 innovative drugs. – In the first half of […]

中國生物製藥(1177.HK)公佈2024中期業績

重點成果 – 期內,集團共有4個創新產品獲中國國家藥品監督管理局(「NMPA」)批准上市,分別為安得衛(貝莫蘇拜單抗注射液)、安柏尼(富馬酸安奈克替尼膠囊)、安洛晴(枸櫞酸依奉阿克膠囊)和貝樂林(利拉魯肽注射液),其中3個為國家1類創新藥。 – 2024年上半年,集團創新產品收入達到61.3億元…